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Risk factors of CRAB bacteremia 935(HR: 3.40; p < 0.001), and previous use of ceftriaxone (HR: 2.51; pZ 0.011). The appropriate-
ness of antimicrobial therapy was 18.87% (20/106) in the mortality group versus 88.16% (67/76)
in the survivor group (p < 0.001). The sensitivity of CRAB to colistin was 100% and to tigecycline
was 40.11%.
Conclusion: The risk factors for mortality for CRAB included intensive care unit stay, a high
Acute Physiology and Chronic Health Evaluation II score, respiratory tract as the origin of
bacteremia, and previous use of ceftriaxone. Early implementation of an antimicrobial agent
that had the highest in vitro activity against CRAB in patients at risk of CRAB bacteremia and
high mortality may improve their outcome.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Acinetobacter species belong to a group of Gram-negative
coccobacilli commonly found both in the environment
(such as in water, food, and soil) and in the humans (such as
in skin, wounds, and respiratory and gastrointestinal
tracts).1 The Acinetobacter calcoaceticuseAcinetobacter
baumannii complex (AB complex) consists of four geno-
typically distinct, but phenotypically very similar, bacterial
species: A. calcoaceticus (an environmental species), A.
baumannii, Acinetobacter pittii, and Acinetobacter
nosocomialis.2e6
In the past decade, AB complex comprising A. bau-
mannii, A. pittii, and A. nosocomialis has become a com-
mon pathogenic cause of health care-associated infections.
Associated infections include pneumonia, urinary tract in-
fections, bacteremia, soft tissue infections, meningitis, and
empyema.2 Carbapenem-resistant strains of AB complex
have been reported worldwide. These antibiotic resistant
strains accounted for 14.1% and 39.4% of all health care-
associated infections in Europe and Latin America,
respectively, with a worldwide prevalence of 30%.7,8 From
2000 to 2005, the prevalence of imipenem-resistant AB
complex in Taiwan increased from 22% to 25%.9 Data from
the Taiwan Surveillance of Antimicrobial Resistance show
that the prevalence of multidrug- and carbapenem-
resistant A. baumannii (CRAB) complex infections has
reached 60e66.8% in recent years.10 The high incidence
rate of CRAB complex infections, especially CRAB, in
Taiwan is a threat to numerous patients in the health care
system and presents a difficult challenge for hospital
infection control. Given limited drug choices and a high
infection mortality rate, treatment of CRAB is difficult.4
Patients with CRAB infections have a higher mortality rate
than those infected with AB strains susceptible to
carbapenem.11e14
The risk factors of mortality of CRAB complex bacter-
emia have been reported in different parts of the world in
recent years.15e20 However, A. baumannii cannot be
differentiated from AB complex using phenotypic
methods.21,22 Currently, only a few articles have reported
the information concerning the comorbidities associated
with mortality risk factors in CRAB bacteremia.23e25 The
aim of this study was to survey mortality risk factors asso-
ciated with CRAB bacteremia.Methods
Bacterial isolates, identification, and clonality
determination
From January 2009 to December 2012, blood isolates of
CRAB complex resistant to imipenem [minimal inhibitory
concentration (MIC)  16 mg/L], according to Clinical and
Laboratory Standards Institute guidelines,26 were collected
in Mackay Memorial Hospital, a 2200-bed, tertiary teaching
hospital in Taiwan. For patients with  2 positive blood
cultures, only the first isolate was included. They were
phenotypically identified as AB complex by the Vitek 2
system (bioMe´rieux Vitek Systems Inc., Hazelwood, MO,
USA) in a microbiology laboratory. Susceptibility tests were
also performed using the Vitek 2 system. Isolates were kept
frozen at 70C in trypticase soy broth (BD, Sparks, MD,
USA) containing 20% glycerol (v/v) until further testing.
Genotypic identification of A. baumannii was performed by
identifying the presence of the blaOXA-51-like carbapene-
mase gene that is specific to the A. baumannii species.27
Identification of other species in AB complex was per-
formed by sequence analysis of rpoB and flanking spaces,
according to the protocol by La Scola et al.28
Finally, isolates were digested with ApaI (New England
Biolabs, Beverly, MA, USA) and evaluated with pulsed-field
gel electrophoresis to determine clonality.29Study population and data collection
We retrospectively reviewed medical charts of patients
infected with CRAB complex and having symptoms and signs
of infection. Patients aged > 1 year were included if they
had bacteremia due to CRAB complex, regardless of pri-
mary infection sites. Patients with CRAB bacteremia were
selected for further clinical analysis after genotypic iden-
tification from CRAB complex. This retrospective study was
approved by the Mackay Memorial Institutional Review
Board (protocol numbers 13MMHIS122 and 13MMHIS291).
Medical records were reviewed and the data on the
following parameters were collected: patient characteris-
tics, source of bacteremia, comorbidities, previous antimi-
crobial use, invasive procedure use (Table 1), whether or not
the patient was in the intensive care unit (ICU) at the time of
Table 1 Risk factors for attributable mortality in 182 patients with CRAB bacteremia
Univariate analysis Multivariate analysis
Mortality
(n Z 106)
Survival
(n Z 76)
Hazard ratio
(95% CI)
p Hazard ratio
(95% CI)
p
Characteristics
Age 69.08 69.20 0.99 (0.98e1.01) 0.373
Sex 63 53 0.97 (0.66e1.43) 0.876
ICU stay 93 46 2.89 (1.61e5.17) <0.001 2.37 (1.26e4.48) 0.008
APACHE II > 20 58 17 2.22 (1.51e3.27) <0.001 2.08 (1.35e3.21) 0.001
Source
Respiratory tract 22 7 2.16 (1.34e3.47) 0.002 3.40 (2.04e5.67) <0.001
Urinary tract 5 10 0.99 (0.40e2.45) 0.990
Skin/soft tissue 4 1 1.83 (0.67e4.98) 0.238
Abdominal route 2 1 1.41 (0.35e5.73) 0.633
Central line 22 19 0.77 (0.48e1.23) 0.275
Primary 51 38 0.80 (0.54e1.17) 0.244
Comorbidities
Hypertension 13 6 1.05 (0.59e1.87) 0.877
CKD 10 6 1.03 (0.54e1.98) 0.928
DM 10 3 1.02 (0.53e1.99) 0.945
CAD 1 2 0.78 (0.11e5.64) 0.809
COPD 4 3 1.22 (0.45e3.33) 0.694
Shock 7 6 1.10 (0.51e2.38) 0.805
Malignancies 15 12 0.82 (0.47e1.41) 0.467
Autoimmune 0 1 d d
Liver cirrhosis 8 3 2.26 (1.09e4.69) 0.028 2.01 (0.96e4.21) 0.064
Neutropenia 0 2 0.05 (0.00e25.08) 0.341
Previous antibiotics
Ceftriaxone 9 2 2.17 (1.08e4.34) 0.029 2.35 (1.16e4.75) 0.017
Ceftazidime 7 9 0.54 (0.25e1.17) 0.119
Ciprofloxacin 8 4 0.74 (0.36e1.54) 0.422
Amikacin 4 3 0.84 (0.31e2.30) 0.740
Piperacillin/tazobactam 26 13 1.13 (0.73e1.77) 0.582
Cefepime 13 2 1.80 (1.00e3.23) 0.051
Colistin 43 32 0.84 (0.57e1.25) 0.399
Tigecycline 14 6 1.27 (0.72e2.24) 0.404
Invasive procedures
Foley catheter 97 63 1.65 (0.83e3.27) 0.153
MV 95 67 0.79 (0.42e1.48) 0.467
CVC 75 48 1.22 (0.80e1.86) 0.354
TPN 11 4 1.03 (0.55e1.92) 0.938
FVC for H/D 45 22 1.20 (0.81e1.76) 0.362
JVC for H/D 8 2 1.32 (0.64e2.71) 0.457
Permanent H/D 31 22 0.89 (0.58e1.35) 0.579
APACHE IIZ Acute Physiology and Chronic Health Evaluation II; CADZ coronary artery disease; CIZ confidence interval; CKDZ chronic
kidney disease; COPD Z chronic obstructive pulmonary disease; CRAB Z carbapenem-resistant A. baumannii; CVC Z central venous
catheter; DM Z diabetes mellitus; FVC Z femoral venous catheter; H/D Z hemodialysis; ICU Z intensive care unit; JVC Z jugular
venous catheter; MV Z mechanical ventilation; TPN Z total parenteral nutrition; d Z not available.
936 C.-P. Liu et al.onset of bacteremia, and the patient’s Acute Physiology and
Chronic Health Evaluation II (APACHE II) score.
Documentation of previous antibiotic use included antibi-
otics that were given to the patient in the14-day period prior
to the onset of bacteremia. Central line-associated infection
was defined according to the United States Centers for Dis-
ease Control and Prevention guidelines.30 Liver cirrhosis was
diagnosed by gastroenterologists based on laboratory
and radiological evidence. Chronic kidney disease was
defined as an estimated glomerular filtration rate of< 60 mL/minute/1.73 m2. An appropriate antimicrobial
therapy was defined as the administration of at least one
antimicrobial agent, to which a pathogen was sensitive
in vitro, within 48 hours of bacteremia, with an approved
route and dosage appropriate for end organ function.
Otherwise, a therapy that did not meet these criteria was
considered inappropriate. A therapy was considered inap-
propriate if only an aminoglycoside was used.31 Attributable
mortality indicated that a patient died during the admission
period of the CRAB bacteremia episode.
Risk factors of CRAB bacteremia 937Statistical analysis
The hazard ratios (HRs) of uni- and multivariate analyses
were performed using a Cox proportional hazards ratio
model (Cox PH regression). For all analyses, a two-tailed
p < 0.05 was considered significant. All biological variables
with p < 0.05 in the univariate analysis were included in the
Cox PH regression for multivariate analysis. SPSS version
21.0 (SPSS Inc., Chicago, IL, USA) was used for performing
the statistical analysis.Figure 1. Demonstration of 38 pulsotypes from 182 Acine-
tobacter baumannii blood isolates. PFGE Z pulsed-field gel
electrophoresis.Results
A total of 195 AB complex blood isolates were collected
during the study period. There were 182 CRAB, 11
carbapenem-resistant A. nosocomialis, and two
carbapenem-resistant A. pittii isolates. The pulsed-field gel
electrophoresis patterns of 182 CRAB isolates were identi-
fied as belonging to 38 different pulsotypes, as presented in
Fig. 1. The attributable mortality rate of the 182 patients
with CRAB bacteremia was 58.24% (106/182). The risk fac-
tors for CRAB mortality are shown in Table 1. The mean age
of 182 patients ( standard deviation) was 69.13  16.31
years. The mean age ( standard deviation) of 106 patients
in the mortality group was 69.08  16.86 years, and that of
76 patients in the survivor group was 69.20  15.73 years.
Male patients accounted for 63.74% of the total 182 pa-
tients, 59.43% of the mortality group, and 69.74% of the
survival group. Of total 182 patients, 139 (76.37%) stayed in
ICU during bacteremia, 93 (87.74%) of whom were in the
mortality group and 46 (60.53%) in the survival group. Of
these 182 patients, 75 [41.21%; 58 (54.72%) in the mortality
group and 17 (22.37%) in the survival group] had APACHE II
scores of > 20. Liver cirrhosis was a univariate risk factor
for attributable mortality among CRAB bacteremia pa-
tients. High mortality (72.73%, 8/11) was found in patients
with liver cirrhosis. Female patients were predominant
among the 11 liver cirrhosis patients (6/11, 55.55%). The
mean age was 65.45  14.34 years. Most of the patients
stayed in ICU (10/11, 90.91%) and had a mean APACHE II
score of 24.18  5.79. Two of the three surviving liver
cirrhosis patients received adequate antibiotics (colistin)
within 24 hours after blood culture, while one of the three
surviving patients did not receive adequate antibiotics
(colistin) until 48e72 hours after positive blood culture.
In multivariate analysis, the independent risk factors for
mortality included stay in ICU [HR: 2.27; 95% confidence
interval (CI): 1.21e4.26; p Z 0.011), APACHE II scores of
>20 (HR: 2.19; CI: 1.42e3.36; p < 0.001), respiratory tract
as the origin of bacteremia (HR: 3.40; CI: 2.04e5.67;
p < 0.001), and use of ceftriaxone prior to the onset of
CRAB bacteremia (HR: 2.51; CI: 1.23e5.09; p Z 0.011).
The sensitivity of CRAB to meropenem was 0% (0/182),
to colistin was 100% (Fig. 2), and to tigecycline was 40.11%.
The MICs of colistin and tigecycline for CRAB are listed in
Fig. 3. Of the isolates, 3.85% and 7.14% had tigecycline MIC
< 0.5 mg/L and MIC < 1.0 mg/L, respectively, while 61.54%
and 76.92% had colistin MIC < 0.5 mg/L and MIC < 1.0 mg/
L, respectively. The percentage of appropriate antimicro-
bial therapy among the182 CRAB bacteremia patients was
18.87% (20/106) in the mortality group versus 88.16%(67/76) among survivors (p < 0.001). The appropriate
therapy included a colistin-based therapy (85 patients; 20
in the mortality group and 65 in the survival group), either a
monotherapy or a combination therapy. Of the patients,
Figure 2. Percentage of susceptibility to antibiotics of 182
CRAB isolates. CRAB Z carbapenem-resistant Acinetobacter
baumannii.
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(colistin-based therapy) survived. Two patients received an
appropriate therapy with tigecycline and both of them
survived after management.Discussion
A. baumannii is distinct from A. nosocomialis and A. pittii
in that it possesses greater antimicrobial resistance and
results in more severe patient outcomes. However, in
routine clinical practice, all these bacteria present similar
phenotypic reactions, cannot be readily identified, and are
instead reported as AB complex.3e6 This generalization
becomes a challenge in research on infections, since the
AB complex infection is caused by a mixture of different
Acinetobacter species. Therefore, it is reasonable to
separate A. baumannii from AB complex in research
studies, and investigate its distinct risk factors and survival
analysis.
With its intrinsic resistance to many antibiotics and rapid
acquirement of resistance mechanisms, A. baumannii
adapts to the hospital environment quickly and can causeFigure 3. MIC values of tigecycline and colistin for 182
carbapenem-resistant Acinetobacter baumannii isolates.
MIC Z minimal inhibitory concentration.outbreaks that are difficult to control.31 CRAB infections
are independently associated with increased hospital mor-
tality, as well as prolonged ICU and hospital stays.12,13 In an
investigation of risk factors for the isolation of multidrug-
resistant A. baumannii, Falagas et al32 suggested that a
separate outbreak investigation should be performed in
each hospital setting, and innovative control strategies
should be developed to limit the spread of pathogens. Since
a central line-associated source (41/182, 22.53%) was
related to CRAB bacteremia, we suggest that a care bundle
intervention be utilized to reduce central line-associated
bacteremia in high-risk units. The central line bundle
would include the several key components according to the
United States Centers for Disease Control and Prevention
guidelines.30 It is hoped that with the implementation of a
central line bundle in our institution, we can decrease in-
cidences of central line-associated bacteremia through
infection control measures. Cleaning of the environment is
also needed for decreasing the incidence of CRAB
overgrowth.
Given that ceftriaxone is ineffective against CRAB, its
previous use was found to be associated with increased
mortality in CRAB bacteremia in this clinical analysis. Our
CRAB isolates from blood showed 100% sensitivity to colistin
and 40.11% sensitivity to tigecycline. In general, colistin is
the preferred drug of choice for treatment of CRAB, except
in the case of severe renal insufficiency. Lee et al33 found
that an appropriate antimicrobial therapy can significantly
reduce the 14-day mortality of patients with A. baumannii
bacteremia. In this study, the rate of appropriate antimi-
crobial therapies for CRAB in the mortality group and sur-
vivors were 18.87% and 88.16% (p < 0.001), respectively.
These results clearly indicate that an appropriate antimi-
crobial therapy can influence the survival rate in bacter-
emia caused by CRAB infections.
The attributable mortality rate of the 182 patients with
CRAB bacteremia was 58.24% (106/182). Liver cirrhosis was
a risk factor for attributable mortality among CRAB
bacteremia patients under univariate analysis. High mor-
tality (72.73%, 8/11) within 14 days after onset of bacter-
emia was found in 11 liver cirrhosis patients with CRAB
bacteremia. There are very few previous large-series
studies regarding A. baumannii infections associated with
liver cirrhosis.34 Four of the 11 liver cirrhosis patients died
within 24 hours after blood cultures were obtained. Two of
the three surviving liver cirrhosis patients received colistin
within 24 hours, while one of the three patients received
colistin within 48e72 hours after blood culture. Controversy
surrounds the benefits of combination treatment or mono-
therapy against multidrug-resistant A. baumannii infections
in clinical practice. According to a systematic review of the
literature, combination treatment may be preferred for
severely ill patients.35 Combination treatment with colistin
is preferred in severely ill patients, for example, ICU pa-
tients with CRAB bacteremia.
The limitation of this study is that this study was con-
ducted in a single medical center, and the results may not
be applied to other hospital. We use attributable mortality
as the endpoint of our study, which is a relatively subjec-
tive endpoint. However, there is also an inherent bias for
using overall mortality in the study of A. baumannii infec-
tion, because the hosts are frequently
Risk factors of CRAB bacteremia 939immunocompromised and had multiple underlying diseases,
which may contribute to the mortality.
In conclusion, the independent risk factors for mortality
in patients with CRAB bacteremia included stay in ICU,
APACHE II scores of > 20, respiratory tract as the origin of
bacteremia, and use of ceftriaxone prior to the onset of
CRAB bacteremia. Rapid identification of patients at risk of
mortality and early implementation of an appropriate
antimicrobial therapy are crucial for patients with CRAB
bacteremia, especially those with liver cirrhosis.
Conflicts of interest
The authors declare that they have no conflicting interests.
Acknowledgments
This study was supported by grants MMH103-33 and MMH
103-61 from Mackay Memorial Hospital, Taipei, Taiwan.
References
1. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl
J Med 2008;358:1271e81.
2. Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic
tests for identification of Acinetobacter species. J Clin Micro-
biol 1991;29:277e82.
3. Nemec A, Krizova L, Maixnerova M, Van der Reijden TJ,
Deschaght P, Passet V, et al. Genotypic and phenotypic char-
acterization of the Acinetobacter calcoaceticuseAcinetobacter
baumannii complexwith the proposal ofAcinetobacter pittii sp.
nov. (formerly Acinetobacter genomic species 3) and Acineto-
bacter nosocomialis sp. nov. (formerly Acinetobacter genomic
species 13TU). Res Microbiol 2011;162:393e404.
4. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii:
emergence of a successful pathogen. Clin Microbiol Rev 2008;
21:538e82.
5. Lee NY, Chang TC, Wu CJ, Chang CM, Lee HC, Chen PL, et al.
Clinical manifestations, antimicrobial therapy, and prognostic
factors of monomicrobial Acinetobacter baumannii complex
bacteremia. J Infect 2010;61:219e27.
6. Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al.
Influence of genospecies of Acinetobacter baumannii complex
on clinical outcomes of patients with Acinetobacter bacter-
emia. Clin Infect Dis 2011;52:352e60.
7. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ.
Antimicrobial susceptibility among organisms from the Asia/-
Pacific Rim, Europe and Latin and North America collected as
part of TEST and the in vitro activity of tigecycline. J Anti-
microb Chemother 2007;60:1018e29.
8. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN,
Bonomo RA. Global challenge of multidrug-resistant Acineto-
bacter baumannii. Antimicrob Agents Chemother 2007;51:
3471e84.
9. Jean SS, Hsueh PR, Lee WS, Chang HT, Chou MY, Chen IS, et al.
Nationwide surveillance of antimicrobial resistance among
non-fermentative Gram-negative bacteria in intensive care
units in Taiwan: SMART programme data 2005. Int J Antimicrob
Agents 2009;33:266e71.
10. Centers for Disease Control. Nosocomial infection surveillance
system. In: Centers for Disease Control, editor. Statistics of
communicable diseases and surveillance report Republic of
China 2010. Taiwan, R.O.C.: Centers for Disease Control,
Department of Health; 2011. p. 42e8.11. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X,
Hebden J, et al. Multidrug-resistant Acinetobacter infection
mortality rate and length of hospitalization. Emerg Infect Dis
2007;13:97e103.
12. Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW,
et al. A multicenter study of risk factors and outcome of hos-
pitalized patients with infections due to carbapenem-resistant
Acinetobacter baumannii. Int J Infect Dis 2010;14:e764e9.
13. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Aci-
netobacter baumannii in intensive care unit patients: risk
factors for acquisition, infection and their consequences. J
Hosp Infect 2007;65:204e11.
14. Lemos EV, de la Hoz FP, Einarson TR, McGhan WF, Quevedo E,
Castaneda C, et al. Carbapenem resistance and mortality in pa-
tients with Acinetobacter baumannii infection: systematic re-
view and meta-analysis. Clin Microbiol Infect 2014;20:416e23.
15. Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, et al.
Combination carbapenemesulbactam therapy for critically ill
patients with multidrug-resistant Acinetobacter baumannii
bacteremia: four case reports and an in vitro combination
synergy study. Pharmacotherapy 2007;27:1506e11.
16. Kim SY, Jung JY, Kang YA, Lim JE, Kim EY, Lee SK, et al. Risk
factors for occurrence and 30-day mortality for carbapenem-
resistant Acinetobacter baumannii bacteremia in an intensive
care unit. J Korean Med Sci 2012;27:939e47.
17. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk
factors for mortality in patients with carbapenem-resistant
Acinetobacter baumannii bacteremia: impact of appropriate
antimicrobial therapy. J Korean Med Sci 2012;27:471e5.
18. Nakwan N, Chokephaibulkit K. Carbapenem-resistant Acineto-
bacter baumannii bacteremia in neonates. Pediatr Infect Dis J
2013;32:197.
19. Thatrimontrichai A, Apisarnthanarak A, Chanvitan P,
Janjindamai W, Dissaneevate S, Maneenil G. Risk factors and
outcomes of carbapenem-resistant Acinetobacter baumannii
bacteremia in neonatal intensive care unit: a case-
ecaseecontrol study. Pediatr Infect Dis J 2013;32:140e5.
20. Yang YS, Lee YT, Tsai WC, Kuo SC, Sun JR, Yang CH, et al.
Comparison between bacteremia caused by carbapenem
resistant Acinetobacter baumannii and Acinetobacter nosoco-
mialis. BMC Infect Dis 2013;13:1e7.
21. Chen TL, Siu LK, Wu RC, Shaio MF, Huang LY, Fung CP, et al.
Comparison of one-tube multiplex PCR, automated ribotyping
and intergenic spacer (ITS) sequencing for rapid identification
of Acinetobacter baumannii. Clin Microbiol Infect 2007;13:
801e6.
22. Chang HC, Wei YF, Dijkshoorn L, Vaneechoutte M, Tang CT,
Chang TC. Species-level identification of isolates of the Aci-
netobacter calcoaceticus-Acinetobacter baumannii complex
by sequence analysis of the 16S-23S rRNA gene spacer region. J
Clin Microbiol 2005;43:1632e9.
23. Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP,
et al. Risk factors and clinical outcomes of patients with
carbapenem-resistant Acinetobacter baumannii bacteremia. J
Microbiol Immunol Infect 2012;45:356e62.
24. Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S,
Markaki V, et al. Carbapenem-resistant versus carbapenem-
susceptible Acinetobacter baumannii bacteremia in a Greek
intensive care unit: risk factors, clinical features and out-
comes. Infection 2010;38:173e80.
25. Le Hello S, Falcot V, Lacassin F, Mikulski M, Baumann F. Risk
factors for carbapenem-resistant Acinetobacter baumannii
infections at a tertiary care hospital in New Caledonia, South
Pacific. Scand J Infect Dis 2010;42:821e6.
26. Clinical and Laboratory Standards Institute. Performance
standards for antimicrobial susceptibility testing: twenty-first
informational supplement. Wayne, PA: CLSI; 2011. CLSI
Document M100eS21.
940 C.-P. Liu et al.27. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME,
Pitt TL. Identification of Acinetobacter baumannii by detection
of the blaOXA-51-like carbapenemase gene intrinsic to this spe-
cies. J Clin Microbiol 2006;44:2974e6.
28. La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the
rpoB gene and flanking spacers for molecular identification of
Acinetobacter species. J Clin Microbiol 2006;44:827e32.
29. Huang LY, Chen TL, Lu PL, Tsai CA, Cho WL, Chang FY, et al.
Dissemination of multidrug-resistant, class 1 integron-carrying
Acinetobacter baumannii isolates in Taiwan. Clin Microbiol
Infect 2008;14:1010e9.
30. O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J,
Heard SO, et al. Guidelines for the prevention of intravascular
catheter-related infections. Clin Infect Dis 2011;52:e162e93.
31. Karageorgopoulos DE, Falagas ME. Current control and treat-
ment of multidrug-resistant Acinetobacter baumannii in-
fections. Lancet Infect Dis 2008;8:751e62.32. Falagas ME, Kopterides P. Risk factors for the isolation of multi-
drug-resistant Acinetobacter baumannii and Pseudomonas
aeruginosa: a systematic review of the literature. J Hosp Infect
2006;64:7e15.
33. Lee YT, Kuo SC, Yang SP, Lin YT, Tseng FC, Chen TL, et al.
Impact of appropriate antimicrobial therapy on mortality
associated with Acinetobacter baumannii bacteremia: relation
to severity of infection. Clin Infect Dis 2012;55:209e15.
34. Badawy AA, Zaher TI, Sharaf SM, Emara MH, Shaheen NE,
Aly TF. Effect of alternative antibiotics in treatment of cefo-
taxime resistant spontaneous bacterial peritonitis. World J
Gastroenterol 2013;19:1271e7.
35. Poulikakos P, Tansarli GS, Falagas ME. Combination antibiotic
treatment versus monotherapy for multidrug-resistant,
extensively drug-resistant, and pandrug-resistant Acineto-
bacter infections: a systematic review. Eur J Clin Microbiol
Infect Dis 2014;33:1675e85.
